X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/new-data-show-rinvoq-upadacitinib-demonstrated-superiority-versus-dupixent-dupilumab-across-primary-and-all-secondary-endpoints-in-an-open-label-head-to-head-atopic-dermatitis-study-302126897.html
https://www.indianpharmapost.com/news/abbvies-phase-3-select-gca-study-of-upadacitinib-showed-positive-results-in-patients-with-giant-cell-arteritis-15560
https://www.fiercepharma.com/pharma/abbvie-touts-rinvoq-win-giant-cell-arteritis-potentially-teeing-another-label-expansion
https://www.prnewswire.com/news-releases/phase-3-select-gca-study-of-upadacitinib-rinvoq-showed-positive-results-in-patients-with-giant-cell-arteritis-302120893.html
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-profit-beats-estimates-humira-botox-sales-weather-hit-rivals-2024-02-02/
https://www.fiercepharma.com/pharma/abbvie-nurtures-another-patent-thicket-time-challenging-sandoz-and-others-efforts-market
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-upadacitinib-extended-release-tablets-3216.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-upadacitinib-extended-release-tablets-30-mg-77681.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-upadacitinib-extended-release-tablets-45-mg-80621.pdf
https://www.clinicaltrialsarena.com/news/abbvie-rinvoq-atopic-dermatitis-2/
https://www.prnewswire.com/news-releases/abbvie-presents-long-term-data-further-supporting-the-efficacy-and-safety-profile-of-rinvoq-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-301952985.html
https://www.newswire.ca/news-releases/health-canada-approves-abbvie-s-rinvoq-r-upadacitinib-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-819598268.html
https://news.abbvie.com/news/press-releases/abbvie-advances-immunology-pipeline-with-first-patient-dosed-in-global-phase-3-trial-upadacitinib-rinvoq-in-hidradenitis-suppurativa.htm
https://www.fiercepharma.com/pharma/abbvies-rinvoq-passes-midstage-test-systemic-lupus-erythematosus
https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-results-from-phase-3-induction-and-maintenance-programs-evaluating-upadacitinib-rinvoq-in-crohns-disease-301834218.html
https://news.abbvie.com/news/press-releases/abbvie-presents-long-term-data-further-supporting-efficacy-and-safety-profile-rinvoq-upadacitinib-across-multiple-rheumatic-diseases-at-eular-2023-congress.htm
https://www.fiercepharma.com/pharma/abbvies-rinvoq-scores-its-7th-fda-nod-one-crohns-disease
https://www.prnewswire.com/news-releases/abbvie-releases-new-data-demonstrating-breadth-of-its-gastroenterology-portfolio-at-2023-digestive-disease-week-301817365.html
https://www.contractpharma.com/contents/view_breaking-news/2023-05-01/abbvie-revenues-down-10-in-the-quarter/
https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-moderately-to-severely-active-crohns-disease-301798397.html
https://news.abbvie.com/news/press-releases/abbvie-advances-upadacitinib-rinvoq-to-phase-3-clinical-trials-in-systemic-lupus-erythematosus.htm
https://www.nasdaq.com/articles/abbvie-gets-positive-chmp-opinion-for-upadacitinib-for-treatment-of-adults-with-crohns
https://www.fiercepharma.com/marketing/abbvie-top-tv-drug-ad-spender-january-rinvoq-skyrizi-continue-winning-streak
https://www.europeanpharmaceuticalreview.com/news/179158/mhra-approves-first-oral-atmp-for-crohns-disease/
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-sales-outlook-two-new-drugs-more-than-175-bln-2025-2023-01-10/
https://www.raps.org/news-and-articles/news-articles/2022/12/asia-pacific-roundup-singapores-hsa-finds-benefits
https://www.pharmatimes.com/news/scottish_medicines_consortium_agrees_to_use_of_rinvoq_1482964
https://www.fiercepharma.com/marketing/abbvies-rinvoq-retakes-crown-sanofis-dupixent-top-tv-drug-ad-spender-november
https://www.fiercepharma.com/marketing/bristol-myers-squibbs-zeposia-abbvies-skyrizi-rinvoq-shaking-early-ibd-treatment-market
https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/
https://endpts.com/abbvie-preps-for-an-onslaught-of-humira-biosimilars-in-2023-with-skyrizi-and-rinvoq-to-fill-the-gap-for-now/
https://www.fiercepharma.com/marketing/abbvie-continues-reign-top-tv-drug-ad-spender-and-pfizers-comirnaty-makes-new-appearance
https://news.abbvie.com/news/press-releases/abbvie-highlights-robust-gastroenterology-portfolio-with-new-data-in-crohns-disease-and-ulcerative-colitis-at-ueg-week-2022.htm
https://www.prnewswire.com/news-releases/rinvoq-upadacitinib-approved-by-european-commission-as-an-oral-treatment-for-adults-with-active-non-radiographic-axial-spondyloarthritis-301595867.html
https://www.prnewswire.com/news-releases/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-in-crohns-disease-301593950.html
https://www.pharmatimes.com/news/nice_recommends_use_of_leo_pharmas_adtralza_1451607
https://www.thepharmaletter.com/article/nice-recommends-abbvie-s-rinvoq-for-atopic-dermatitis
http://www.pharmafile.com/news/664356/nice-recommends-dermatitis-treatment-use-nhs-england-and-wales
https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-upadacitinib-rinvoq-for-the-treatment-of-adults-with-active-non-radiographic-axial-spondyloarthritis-301574375.html
https://www.fiercepharma.com/marketing/abbvie-revs-rinvoq-first-eczema-ad-feels-90s-rave-spliced-air-force-recruitment-video
https://www.prnewswire.com/news-releases/the-lancet-publishes-results-from-phase-3-induction-and-maintenance-programs-evaluating-upadacitinib-rinvoq-in-ulcerative-colitis-301556455.html
https://news.abbvie.com/news/press-releases/chmp-recommends-european-commission-approval-upadacitinib-rinvoq-for-treatment-adults-with-moderate-to-severe-ulcerative-colitis.htm
https://endpts.com/rinvoq-passes-phiii-maintenance-study-for-crohns-disease-potentially-setting-the-stage-for-label-expansion/
https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-receives-fda-approval-for-treatment-adults-with-moderately-to-severely-active-ulcerative-colitis.htm
https://www.prnewswire.com/news-releases/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-and-endoscopic-outcomes-in-patients-with-crohns-disease-301489240.html
http://www.pharmafile.com/news/606998/abbvie-submits-applications-treatment-chronic-disease
https://endpts.com/ema-initiates-safety-review-on-jak-inhibitors-galapagos-woes-continue-as-it-terminates-latest-study/
https://www.prnewswire.com/news-releases/abbvie-showcases-its-leadership-in-research-in-inflammatory-bowel-diseases-with-new-analyses-to-be-presented-at-the-17th-congress-of-european-crohns-and-colitis-organization-ecco-301472617.html
https://news.abbvie.com/news/press-releases/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm
Market Place
Share 
